Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shebone XT is a multi-ingredient therapeutic supplement developed by Neurogenics Therapeutics, primarily indicated for the management of bone-related disorders and associated nutritional deficiencies. The formulation typically combines **calcium carbonate** and **calcitriol** (the active form of Vitamin D3) to enhance intestinal calcium absorption and promote bone mineralization, making it effective for conditions such as osteoporosis and osteomalacia. Additionally, it incorporates a complex of B-vitamins, including **methylcobalamin** (Vitamin B12), **folic acid**, and **pyridoxine** (Vitamin B6). These vitamins work synergistically to lower homocysteine levels and support neuronal health, providing a comprehensive approach to managing both bone density loss and peripheral neuropathy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shebone XT.